BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data ...
bdtonline.com
news
2022-10-17 16:32:40

- BridgeBio to host investor call today (October 17, 2022) at 1:30 pm ET to discuss its two most advanced RAS precision oncology programs –KRASG12CGTP/GDP dual inhibitordevelopment candidate BBO-8520, and its novelPI3Kα:RASbreaker mechanism which is in late lead optimization- KRASG12CGTP/GDP dual inhibitor BBO-8520 has shown significantly greater potency in KRAS models than first-generation KRASG12CGDP-only inhibitors as measured by its ability to bind and covalently modify KRASG12C, block KRASG1
